DLin-MC3-DMA
DC10800
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | 871258-12-7 |
| Chemical Name | DLinDMA |
| Synonyms | DLinDMA;1,2-dilinoleyloxy-n,n-dimethyl-3-aminopropane;WJB25812;1,2-dilinoleyloxy-3-dimethylaminopropane;E74884;1-Propanamine, N,N-dimethyl-2,3-bis[(9Z,12Z)-9,12-octadecadienyloxy]- (9CI);N,N-Dimethyl-2,3-bis[(9Z,12Z)-9,12-octadecadien-1-yloxy]-1-propanamine (ACI);1,2-Dilinoleyloxy-N,N-dimethylaminopropane;N,N-Dimethyl-2,3-bis(((9Z,12Z)-octadec-9,12-dien-1-yl)oxy)propan-1-amine;N,N-Dimethyl-2,3-bis[(9Z,12Z)-octadeca-9,12-dienyloxy]propan-1-amine,D-LinDMA， D-Lin-DMA; |
| SMILES | O(CCCCCCCC/C=C\C/C=C\CCCCC)C(CN(C)C)COCCCCCCCC/C=C\C/C=C\CCCCC |
| Formula | C41H77NO2 |
| M.Wt | 616.072 |
| Purity | >95% by ELSD-HPLC |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Carrasco MJ, Alishetty S, Alameh MG, et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Communications Biology. 2021;4:956. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nature Biotechnology. 2010;28:172-176. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| DLin-DMA | 50 | Ionizable lipid |
| DSPC | 10 | Helper phospholipid |
| Cholesterol | 38.5 | Sterol |
| DMG-PEG2000 | 1.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Component molecular weights and calculated amounts
Composition retained from the cited study below. Research planning aid only. Results cover lipid component weights and do not include RNA, buffer, solvent, process loss or an N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| DLin-DMA | 50.000 | 87.1815 | 53.7101 | ||
| DSPC | 10.000 | 17.4363 | 13.7773 | ||
| Cholesterol | 38.500 | 67.1297 | 25.9557 | ||
| DMG-PEG2000 | 1.500 | 2.6154 | 6.5569 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Literature-reported performance for the cited formulation
Calculated from published source data251-335 RLU at 25 ng; 1543-1920 RLU at 200 ngHEK293, 24 h after transfection, n=3 · Common five-lipid comparison; authors reported KC2 > MC3 > DLin > DODMA > DODAP under these conditionsRange calculated from the three published source-data replicates at each selected dose; intermediate 50 and 100 ng data remain in the source workbook.Main p.5 Fig.3a; Supplementary Data 3, 'Figure 3a'!B3:N7; DLin row B5:N5
Calculated from published source data61.59-68.35 million photons/s at 4 h; 7.844-15.64 million photons/s at 24 h5 micrograms FLuc mRNA-LNP/mouse, IM; female BALB/c mice · 4 and 24 h · Five ionizable-lipid formulations at the same composition and N/PRanges calculated from published source-data values.Main p.7 Fig.4c; Supplementary Data 4, 'Figure 4c'!B5:H5
Calculated from published source data401.8 and 594.7 million photons/s at 4 h; 35.79-190.3 million photons/s at 24 h5 micrograms FLuc mRNA-LNP/mouse, IV; female BALB/c mice · 4 and 24 h · Five ionizable-lipid formulations at the same composition and N/PPublished source-data values; the 4 h sheet contains two DLin values, so no missing third replicate was invented.Main p.7 Fig.4d; Supplementary Data 4, 'Figure 4d'!B5:H5
Published particle and ionization measurements
| Parameter | DLin-DMA result | Source |
|---|---|---|
| DLS number diameter | 62.79 and 69.72 nm | Source Data Fig.3b |
| PDI | 0.246 and 0.249 | Source Data Fig.3b |
| Encapsulation efficiency | 72.95% and 74.72% | Source Data Fig.3d |
| TNS apparent LNP pKa | 6.66 | Source Data Fig.1d |
| Zeta-potential pKa / pI | 6.15 / 6.34 | Source Data Fig.1d |
| Water-soluble analogue pKa | 8.93 | Source Data Fig. 1d |
Carrasco et al. 2021 main Table 1 and Figs.1,3; Supplementary Data 1 'Figure 1d'!B2:G7 and Supplementary Data 3 'Figure 3b'!B2:F7, 'Figure 3d'!B2:F7
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetCarrasco MJ, Alishetty S, Alameh MG, et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Communications Biology. 2021;4:956. DOI: 10.1038/s42003-021-02441-2
The page formulation and all particle/in vivo values use the Carrasco 2021 50:10:38.5:1.5, N/P 4 FLuc mRNA-LNP. Semple 2010 data are separately labelled as a 40 mol% PFV screen with incomplete helper-lipid composition and are not merged with the 2021 formulation.
The page formulation and all particle/in vivo values use the Carrasco 2021 50:10:38.5:1.5, N/P 4 FLuc mRNA-LNP. Semple 2010 data are separately labelled as a 40 mol% PFV screen with incomplete helper-lipid composition and are not merged with the 2021 formulation.
Published study figures
Original publication figures illustrating the cited formulation and biological results. Select an image to view it at full size.
Figure 3 — Cell expression, viability and LNP characteristics
DLinDMA (labelled DLin) is compared with KC2, MC3, DODMA and DODAP. Luciferase expression and cell viability are shown across mRNA doses; the particle-size and encapsulation measurements refer to the same study formulations. HEK293 cells; FLuc mRNA; N/P 4; 25–200 ng mRNA; 24-hour cell assessment; mean ± SD, n=3.
Carrasco et al. (2021), Communications Biology, Figure 3. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.
Figure 4 — Route-dependent reporter expression in mice
DLinDMA (DLin), MC3, DODMA and DODAP are individually labelled alongside KC2. The relative performance changes between intramuscular and intravenous administration; results should be read within the route and time point shown. 5 µg FLuc mRNA per mouse; N/P 4; IM or IV; measurements at 4 and 24 hours.
Carrasco et al. (2021), Communications Biology, Figure 4. CC BY 4.0. Original figure unchanged. Original article / figure · CC BY 4.0. Unmodified complete original figure; displayed at responsive size.